| March 10, 2008 |
| April 1, 2008 |
| February 2003 |
| |
| Endpoints will be the AUC and Cmax for desloratadine, 3-OH desloratadine, and fexofenadine. [ Time Frame: Serial, Trough, and Terminal blood samples over 8 days. ] [ Designated as safety issue: No ] |
| Same as current |
| Complete list of historical versions of study NCT00636870 on ClinicalTrials.gov Archive Site |
| Endpoints will include Tmax, elimination half-life (t1/2), and accumulation index, as the data permit. [ Time Frame: Serial, Trough, and Terminal blood samples over 8 days. ] [ Designated as safety issue: No ] |
| Same as current |
| |
| Fexofenadine (Allegra®) in Healthy Adults Who Have Been Identified as Slow Metabolizers for Desloratadine |
| A Randomized, Double-Blind, Repeat-Dose, Crossover Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Desloratadine (Clarinex®) Compared to Fexofenadine (Allegra®) in Healthy Adults Who Have Been Identified as Slow Metabolizers for Desloratadine. |
To evaluate the single-dose and steady-state pharmacokinetics of desloratadine and fexofenadine in desloratadine slow metabolizers. To evaluate the safety and tolerability of desloratadine compared to fexofenadine following single and multiple oral doses administered to desloratadine slow metabolizers. |
| |
| Phase IV |
| Interventional |
| Treatment, Randomized, Double-Blind, Crossover Assignment |
| Allergic Rhinitis |
| Drug: Fexofenadine |
| |
| |
| |
| Completed |
| 220 |
| January 2004 |
|
Inclusion Criteria:
- Healthy, adult, non-smoking males and females between 18 and 55 years of age, inclusive; Whites of European or North American heritage and Blacks of African or Caribbean heritage.
Exclusion Criteria:
- Any past or present clinically relevant abnormality, medical condition, or circumstance making the subject unsuitable for participation in the study.
- Historical, clinical, or laboratory evidence of liver disease including but not limited to transaminase activity concentrations >2.5 times the upper limit of the reference range.
- Active peptic ulcer disease or a history of gastrointestinal surgery within the last 6 months.
- History of cholecystectomy.
- History of malignancy within the last 5 years (except basal cell carcinoma, which must be in remission for at least 6 months prior to the study.
- Pregnant or lactating females or females of childbearing potential who are unwilling to use reliable, medically accepted methods of contraception. If subjects who are not sexually active with members of the opposite sex become so during the study, these subjects must agree to use a medically accepted method of contraception.
- History of hypersensitivity or intolerability to either desloratadine or fexofenadine or other antihistamines.
- Treatment with other antihistamines in the last month before study entry.
- Use of any prescription or over-the-counter medications or dietary/herbal supplements (with the exception of oral or implanted contraceptives) within 1 week or 5 half-lives, whichever is longer, of the study.
- History of alcoholism or drug abuse within 12 months of the study.
- Ingestion of alcohol within 1 week of the first dose of study medication.
- Ingestion of grapefruit or grapefruit juice within 1 week of the study and a willingness to abstain from the consumption of grapefruit or grapefruit juice for the duration of the study.
- Participation in any other clinical trial or use of an investigational product within 30 days of entry into the study.
|
| Both |
| 18 Years to 55 Years |
| No |
| Contact information is only displayed when the study is recruiting subjects |
| United States |
| |
| NCT00636870 |
| Study Director, sanofi-aventis |
| M016455/4124 |
| Sanofi-Aventis |
|
| Study Director: |
Phyllis Diener |
Sanofi-Aventis |
|
|
| Sanofi-Aventis |
| April 2008 |
